- Conditions
- Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
- Interventions
- Clazakizumab
- Drug
- Lead sponsor
- Stanley Jordan, MD
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 22, 2026, 2:48 AM EDT